Ubamatamab — Investigational Agent
T-Cell Engager · Phase 1/2 · Regeneron
Mechanism of Action
A MUC16 x CD3 bispecific antibody that bridges CD3-expressing T cells to MUC16 (CA-125)-expressing ovarian cancer cells, triggering T-cell-mediated tumor cell killing.
Investigational Indications
- Recurrent ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer